Hydroxyprogesterone heptanoate
Progestin; Progestogen ester | |
ATC code | ) |
---|---|
Identifiers | |
| |
JSmol) | |
| |
|
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a
OHPH is a progestin, or a
OHPH was first described by 1954[16] and was introduced for medical use by 1957.[6] It has been used clinically in France and Monaco in the past but is no longer marketed.[2][3][4]
Medical uses
OHPH is a progestogen and was used in situations in which progestogens were indicated.[12][13][14]
Available forms
OHPH was provided as a 125 mg/1 mL
Pharmacology
Pharmacodynamics
OHPH is a progestin, or a
Pharmacokinetics
OHPH shows a pronounced
Chemistry
OHPH, also known as hydroxyprogesterone enanthate (OHPE),
History
OHPH was first described, along with hydroxyprogesterone caproate and hydroxyprogesterone acetate, by Karl Junkmann of Schering AG in 1954.[16][19] It was introduced for medical use by 1957.[6] OHPH was commercialized by Roussel and Théramex, and has been used clinically in France and Monaco but is no longer marketed.[2][3][4]
Society and culture
Brand names
OHPH has been marketed alone under a number of brand names including H.O.P, Hydroxyprogesterone, Lutogil A.P., and Lutogyl A.P.[1][2][3][4]
Availability
OHPH was previously marketed in France and Monaco but is no longer available.[2][3][22]
See also
- Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate
- Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate
- Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate
- Progesterone/hydroxyprogesterone heptanoate/α-tocopherol palmitate
References
- ^ ISBN 978-1-4757-2085-3.
- ^ ISBN 978-3-88763-075-1.
- ^ ISBN 978-3-7692-2114-5.
- ^ ISBN 978-3-13-558404-1.
- ^ a b c Sasco AJ, Gendre I, Verbier-Naneix C, Soulier JL, Raffi F, Satgé D, Robert E (1998). "Neonatal neuroblastoma and in utero exposure to progestagens". International Journal of Risk and Safety in Medicine. 11 (2): 121–128.
- ^ a b c d e Ermiglia G, Valli P (1957). "Triormon depositum in climacteric syndrome. Curves of excretion of catabolites and duration of the therapeutic effect". Quaderni Clin. Ostet. E Ginecol. 12: 284–93.
Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
- ^ ISSN 0037-1777.
The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.
- ^ a b c Excerpta medica. Section 8, Neurology and neurosurgery. 1981. p. 10.
- ^ ISBN 978-1-4816-9288-5.
- ^ ISBN 9780444420169.
- ^ ISBN 978-0-8493-4307-0.
Progestogens. [...] Hydroxyprogesterone heptanoate. Hydroxyprogesterone (Theramex). Oily solution for injection.
- ^ S2CID 32126275.
- ^ PMID 26327902.
- ^ PMID 10928425.
- ^ ISBN 978-3-662-00826-3.
- ^ S2CID 33591186.
- ^ a b c Junkmann K (1959). Über Entwicklungen auf dem Gestagengebiet. 15. General Assembly of the Japan Medical Congress, Tokyo. Vol. 1. pp. 697–706.
- ^ "Formulation".
- ^ ISSN 0022-3263.
- ISBN 978-1-4832-7276-4.
- PMID 13828402.
- ^ "OHPH". micromedexsolutions.com.